USTC Global on X: "The mechanism of using Tocilizumab to cure severe patients of COVID-19. @NIH @CDC @DrAiLynTan #coronavirus #COVID19 #CoronavirusOutbreak #coronaviruskorea #ItalyCoronavirus #italylockdown #IranCoVidTruth #Tocilizumab https://t.co ...
Is PMR the Next Indication for Tocilizumab? | MedPage Today
Roche warns of shortage of Covid-19 drug tocilizumab - The Hindu BusinessLine
Roche Suspends Patents On Tocilizumab In LMICs After WHO Recommends It As Treatment For Severe COVID-19 - Health Policy Watch
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QFWUTH5BLZN5LGWVT27LGWPZBE.jpg "Roche arthritis drug reduces COVID-19 deaths in trial in hospitalised patients | Reuters")
Roche arthritis drug reduces COVID-19 deaths in trial in hospitalised patients | Reuters
Approval lapsed) RoActemra tocilizumab 80mg/4mL concentrate for solution for infusion (Roche Germany) | Therapeutic Goods Administration (TGA)
Roche to boost Tocilizumab supply to meet rising demand in India - The Economic Times
CHMP backs expanded approval of tocilizumab | MDedge Hematology and Oncology
Actemra; coronavirus complications to be treated under Chinese approval
Tocilizumab May Benefit Certain Severe COVID-19 Patients | MedPage Today
Roche arthritis drug cuts deaths in hospitalized COVID-19 patients, study suggests | CBC News
Roche | Actemra/RoActemra (tocilizumab)
WHO adds Roche's arthritis drug tocilizumab to COVID-19 medicines list | Reuters
:quality(90)/ "Roche | Actemra")
Roche | Actemra
WHO prequalifies Roche's tocilizumab as its first monoclonal antibody treatment for COVID-19 - Homeland Preparedness News
Genentech's arthritis drug tocilizumab shows promise in Covid-19 trial
WHO Urges Covid-19 Treatment With Roche and Sanofi Anti-Inflammatory Drugs - WSJ
Roche gives Tocilizumab worth over Rs 40 crores to MoHFW - Express Pharma
Drug vignettes: Tocilizumab - The Centre for Evidence-Based Medicine
Coronavirus : l'Actemra de Roche marque un point contre le Covid 19 | Les Echos
FDA approves drug to treat CRS induced by CAR T-cell therapy | MDedge Hematology and Oncology
FDA approves Roche's Actemra for COVID-19
Roche won't contest Hetero Drug's tocilizumab copy | Mint
Roche's Actemra fails to meet Phase III goals in Covid-19 patients
Approval lapsed) RoActemra tocilizumab 400 mg/ 20mL concentrate for solution for infusion (Roche Germany) | Therapeutic Goods Administration (TGA)
Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential - Ghasemi - 2022 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
